LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.

Financial details of the deal were not disclosed.

The partners plan to enter into a global licence arrangement for the technology.

Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.

In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.

Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels

As usual, pls do ur own research.

Quite a lot of interest again with volume up, maybe some news.

chart above not up dating...up another 7% today something brewing

This train's getting ready to leave the station with or without the sceptics on board.

GL + ADYOR.

Went into local Holland and Barrett on Saturday to buy Sirco, salewoman said Sirco flying off the shelves!

Provexis PLC



Pre-close trading update



A Year of Strong Progress



Provexis plc (PXS.L) ("Provexis" or the "Company"), which focuses on the discovery, development and licensing of scientifically-proven functional food, medical food and dietary supplement technologies announces a pre-close trading update for the year ended 31 March 2010.



In its preliminary results statement expected mid May, the Company expects to report on a year of strong progress in strengthening its platform for the development and commercialisation of functional food, medical food and dietary supplement technologies within its target sectors. The directors believe that the functional food, medical food and dietary supplements sectors continue to be rich in opportunity given their size and the industry forecasts of growing consumer demand.



The principal focus in the past year has been on the delivery of Fruitflow which resulted in a series of significant announcements being made over the past 11 months demonstrating the product's efficacy and potential market demand.



Fruitflow



A series of human trials, most recently this month successfully comparing the anti-thrombotic effects with Aspirin, demonstrate Fruitflow's proven ability to reduce platelet aggregation leading to healthy blood flow. The benefits are seen quickly and last for eighteen hours making it ideal for daily dosage in functional foods or dietary supplements. The technology was, in May, the first product to be substantiated by the European Food Safety Authority under the new Article 13(5) of Regulation 1924/2006 for proprietary and emerging science. Moreover, in December the European Commission authorised the health claim "Helps maintain normal platelet aggregation, which contributes to healthy blood flow". Fruitflow continues to be the only product to receive approval under Article 13(5).



In February 2010, Provexis announced that it had entered into a Letter of Intent ("LOI") with DSM Nutritional Products ("DSM") for the Company's Fruitflow technology. The LOI, which provides a framework for the parties to develop a long-term Alliance Agreement giving DSM the exclusive global rights to Fruitflow, is progressing as expected and the Company looks forward to announcing details in due course.



DSM Nutritional Products is the world's leading supplier of vitamins, carotenoids and other fine chemicals to the feed, food, pharmaceutical and personal care industries and has collaborated with Provexis on an informal basis for some time before the LOI was entered into.



Technology Pipeline



The Company's joint venture with the University of Liverpool in relation to its NSP#3G plantain extract for Crohn's disease and Clostridium difficile is proceeding on plan. First patient trials for Crohn's disease have begun and the Directors look forward to updating shareholders on the progress of this trial by the end of 2010.



The Company is also assessing a number of other technology candidates, including an extract for reduction of cardiovascular inflammation. The Directors expect to provide greater detail on the progress of these candidates in the full year results.



Financial Position



The Company raised 7.1 million in 2009 via a subscription in September and a open offer in December. Following receipt of these funds, the Company expects to report net cash of 7.0 million at the year-end. This cash provides the Company with the platform to continue its progress to date and to fund the development of its functional and medical food technology pipeline.



The Company is also pleased to announce today in a separate announcement that it has entered into a 25 million Equity Financing Facility. This facility provides the Board with the financial flexibility to accelerate the development of current technologies in order to maximise investment returns and/or acquire new technology opportunities.





Stephen Moon, CEO of Provexis, commented:



"We anticipate continuing news relating to the DSM alliance in the coming financial year, but more than this, with our pipeline of new technologies developing well, we plan to move additional products rapidly up the value chain.



"We have stated our acquisition policy in the past and have entered into exploratory talks with a number of targets and look forward, with significant financing now in place, to keeping shareholders abreast of developments"

31 March 2010



ALL LOOKS GOOD TO ME.

wonderful news, plus all those patents. Money should come flooding in soon, time to top up i reckon.

TIDMPXS

RNS Number : 7429K
Provexis PLC
26 April 2010


26 April 2010

Provexis PLC

Collaboration Agreement

Strengthened pipeline through tie-up with Institute of Food Research

Provexis plc ("Provexis" or the "Company"), the life-science business that
discovers, develops and licenses scientifically-proven functional food, medical
food and dietary supplement technologies, announces that it has entered into a
long-term research and development collaboration agreement with the Institute of
Food Research ("IFR") and Plant Bioscience Limited ("PBL') the technology
transfer company for IFR. As part of the agreement, Provexis has been granted
exclusive access to a portfolio of potentially high-value intellectual property
related to the treatment and reduction of systemic inflammation, from which it
intends to develop commercial products.

Professor Richard Mithen of IFR has developed a substantial body of work over
twenty years in the area of isothiocyanates for the reduction of risk of certain
major cancers. More recent work, some in collaboration with Provexis, has led to
the discovery of a broader effect in other areas of systemic inflammation,
including cardiovascular inflammation. As a result patents for a novel extract
were filed jointly by Provexis, IFR and PBL in 2008.

This new collaboration gives Provexis a broad range of exclusive rights to the
background and joint intellectual property. The partners will collaborate to
develop the science, with major areas including clinical trials, extract
development, further IP development, regulatory clearances and
commercialisation. The first phase of the project gives Provexis the exclusive
option to license the technology from IFR and PBL and if successful in this
phase, Provexis intend to move to fully in-license the technology rights.

Initially the Company, supported by IFR's substantial research, will focus on
developing commercial products targeting the reduction of cardiovascular
inflammation. A second, longer-term objective is to develop technologies
designed to mitigate the risk of certain major cancers.

Stephen Moon, CEO of Provexis said:

"The collaboration with IFR is a further step in the continued expansion of
Provexis and its product pipeline. The initial work to develop a cardiovascular
claim and product complements our already recognised expertise in the heart
health arena and in the longer term we feel we are ideally positioned to develop
technologies that work to reduce the risk of some major cancers. This new
venture further strengthens our pipeline and is an important element in creating
long term shareholder value."

seems to be heading down, next stop 3p?

slipping under the radar, PXS is having a stonking day (no, not stinking!) and is +36% (a whole 1.39p!) on very heavy volume

Something a foot me thinks. Hopefully news of DSM deal signing. And further news

Further news out today in the form of the accounts.

Headlines for me:

Revenue - 14k
Loss - 1.7m

Fees of 1.2m to raise the last lump of cash!!

Director salaries (Moon - 200k) & share options.

SP heading sub 3p.

it's always good to see the directors looking after themselves properly .... heaven forbid the company should be making a profit first

Those results were announced by PXS on the 1st June (Prelims), so there is nothing new. There is no subsequent, worthwhile, significant news though. Will PXS have something staggering to tell us on or before their AGM on 9th September? Or will we just be staggered?! :0)

perhaps the directors will be asked to explain how they manage to justify paying themselves so handsomely when the company is smaller than our little private one here - and we make a consistent profit!

Hmm, yes, the shareholders have been Mooned!

I posted only Moon's renumeration, the total package for all directors is a staggering 500k approx; for a company that managed revenues of 14k.

They work on the same principles as the banks obviously!

wonder if i can be bothered to get off my arse and go down the road to make a nuisance of myself in Reading

You give um hell from me cyners....thata boy.,. I can only drink so much of the stuff and the sp hasn't shifted...